Your device is a data business. Plan it that way from day one.

TL;DR

Here’s what determines whether a connected device becomes a data business or just a device with a subscription bolted on:

Half of the medtech leaders in Deloitte’s 2025 connected care survey expect connected care to make up 61 to 100 percent of their organization’s product portfolio within five years. The same report cautions that market adoption faces three key gaps that must be closed: simplifying workflow integration via interoperability and end users understanding, more compelling research to demonstrate end-user value, and resolving ambiguities around data authorization.

Those gaps, between boardroom ambition and market reality, are part of the reason a digital strategy is hard to pin down. Do you wait on data infrastructure and bolt it on once the market catches up, or do you architect the product around connectivity from day one? Get the timing wrong and you pay for it twice, once in redesign cost and once in the market position a faster competitor claims while you wait.

The answer depends on what the data is worth, and on who it is worth something to. Most teams defer that question until the architecture is already fixed, which is the expensive order to do it in. The use case below shows what gets decided in the deferral. The patient and her care team are composite, drawn from patterns common in connected therapy programs, but the mechanics are in production today.

Usage data can catch health problems early

Consider a patient eight months into connected sleep therapy following a diagnosis of sleep apnea. Her therapy index, normally stable at 2.4 events per hour, climbs to 18.7 over six nights. Mask leak triples. Nightly usage hours fall. None of it is visible to her, and none of it would reach her clinic before her next scheduled appointment. The device’s cloud platform flags the pattern as a high-priority clinical alert and pushes it to the sleep clinic’s dashboard overnight.

A care coordinator calls the next morning. The patient mentions she has been sleeping in a recliner because of leg swelling. That detail, combined with the data pattern, prompts a same-day cardiology referral. New-onset atrial fibrillation and early congestive heart failure, caught before a likely hospitalization.

The data that made the call possible was not collected for cardiology. It was collected to document therapy adherence for an insurer. One feed, built to satisfy a billing requirement, produced a clinical save for the patient, a proactive intervention for the care team, an avoided admission worth roughly $19,000 for the payer, and evidence for the manufacturer that nightly therapy data can predict cardiac events. That is the pattern worth planning around, and it is also the pattern that pays. It pays more than once.

Connected hardware sells once. The data it generates sells twice more.

A connected medical device company sells hardware. That’s payment one. But the data generated by that hardware, continuously, longitudinally, at population scale, is the engine behind two more revenue streams that are, in aggregate, worth more than the device itself.

The data asset itself becomes a product. Aggregated and de-identified, population data can be licensed to pharma and research partners, used to train proprietary algorithms, and fed into adjacent SaaS businesses. The same stream that began as a compliance record becomes an R&D asset, and a competitive moat that hardware alone never creates.

• The provider pays for the platform. Clinics, hospital systems, and DME suppliers pay a subscription fee for the clinician-facing dashboard: patient alerts, compliance reports, population analytics. The device creates the need for the software, and the software creates a recurring revenue contract.
• The insurer pays because the data proves value. Many payers now require documented adherence or outcome data before continuing device coverage. Without the data infrastructure, there may be no reimbursement pathway. The device isn’t just a product, it is a credentialing mechanism.
• The data asset itself becomes a product. Aggregated and de-identified, population data can be licensed to pharma and research partners, used to train proprietary algorithms, and fed into adjacent SaaS businesses. The same stream that began as a compliance record becomes an R&D asset, and a competitive moat that hardware alone never creates.

Four stakeholders pay for the same data stream, for four different reasons

Four stakeholder groups, four different motivations, four distinct opportunities. Patients get earlier intervention, with deterioration caught before it becomes a crisis. Providers get billable remote-monitoring workflows and the outcomes data that value-based contracts require. Payers get proof of avoided cost: fewer ER visits, fewer admissions. Pharma and researchers get de-identified, real-world cohorts for trials and post-market studies. Understanding all four is what separates a data strategy from a data feature.

Across the medical device industry, companies with connected data platforms are valued at a premium of roughly 30 to 50 percent over hardware-only businesses, though that figure comes from M&A comparables rather than early-stage rounds. Investors price recurring software revenue differently than one-time device sales. If you’re raising capital, the story you’re telling matters.

Digital strategy is a staged bet, not a single leap

Digital health strategy is inherently multiphase. A strategy may start with connectivity, then a clinical study cloud, then clinician APIs or dashboards, then population analytics, then AI model development, then adaptive algorithms, then autonomous decision support. Each phase is a distinct investment window and a distinct business opportunity: a services contract, then a subscription product, then a data-licensing business, then additional regulated software products in their own right.

Waiting costs more than the infrastructure does

The objection most founders raise is reasonable: “We’re pre-revenue. We can’t afford to build a cloud platform on top of the device.” That framing is risky. Affordability today does not change the need to be ready, or the opportunities lost without a plan. The first stage is smaller than the objection assumes. Designing the connectivity architecture early may only add tens of thousands of dollars but keeps later stages from turning into redesigns.

None of that depends on ambition or on a funding round. It depends on requirements that are already in force.

• Reimbursement increasingly requires data. CMS Remote Patient Monitoring codes (CPT 99457 and 99458) require documented clinical time driven by data review. Without automated data capture, you may be ineligible for billing codes your competitors already use.
• Value-based contracts require proof. You can’t negotiate outcomes-based contracts without cohort-level evidence that your device reduced hospitalizations or improved adherence.
• Data is a moat hardware never will be. A competitor can reverse-engineer your form factor. They cannot replicate five years of longitudinal data, trained algorithms, and network effects.
• Retrofitting costs more than building right. Adding connectivity later often means redesigning hardware, resubmitting for FDA clearance, and rebuilding architecture and contracts from scratch.
• Customers already expect it. Hospital systems and major DME suppliers have workflows and billing built around connected-device data feeds.

Building right means staging the architecture, not buying a platform on day one

You don’t need an enterprise platform on day one. You do need a roadmap that stages the architecture toward the platform you will eventually run, and that matches how the business is meant to grow. The sequence below stages capability in the order the business needs it, and each stage earns something before the next one is funded.

• Device-level connectivity. Cellular or Bluetooth to a companion app, transmitting session data and alert-threshold events automatically.
• De-identification and data governance. HIPAA Safe Harbor de-identification, consent management, and audit trails need to exist before your first data-partnership conversation, not after.
• HIPAA-compliant cloud back end. Purpose-built health cloud services provide the Business Associate Agreement, audit logging, and interoperability standards (HL7 FHIR) that clinical integrations require.
• Clinician-facing interfaces and APIs. Even a simple portal showing compliance, alerts, and cohort summaries gives clinical customers something to bill and report against, and gives you subscription revenue.
• Patient-facing app, portals, and APIs. Patient engagement drives adherence, which drives data quality, which drives the value proposition to payers and providers.

Related Resources

How to Compare Medical Device Engineering Firms Beyond Hourly Rates

The hourly rate is only a starting point when you choose a medical device engineering firm. Learn how to judge team staffing, in-house disciplines, facilities, ISO 13485 scope, and track record before you sign.

Connected Medical Devices Are Coming, Just Not as Fast as the Boardroom Expects

Medtech leaders expect connected products to take over their portfolios within five years. Three years of actual FDA clearance filings show a real climb, just a much more gradual one.

Regulatory Clearance Is Not Commercial Readiness

Learn why supply chain, process, cost, and quality gaps stall cleared devices, and why they are decided during design.

Project Estimation Pitfalls: Ten Ways Good Estimates Go Wrong

From skipping the doers to estimating toward a target budget, these ten project estimation pitfalls explain why good estimates go wrong and what to do instead.